Literature DB >> 3550023

Clinical course of immunoglobulin A nephropathy in children.

N Yoshikawa, H Ito, S Yoshiara, C Nakahara, K Yoshiya, O Hasegawa, T Matsuo.   

Abstract

The clinical presentation, initial laboratory and renal biopsy findings, and subsequent clinical course of IgA nephropathy were studied retrospectively in 200 children, and findings in those with younger onset and older onset were compared. Eighty-three patients were 8 years of age or younger (group 1) and 117 were 9 years of age or older (group 2) at onset. There were no differences between the two groups with regard to sex, initial renal function, incidence of hypertension and macroscopic hematuria, degree of proteinuria, and pathologic findings. At the latest follow-up, two patients in group 1 and eight in group 2 had chronic renal failure, and five patients in group 1 and 21 in group 2 had heavy proteinuria with or without hypertension (P less than 0.01), whereas 36 (43%) patients in group 1 and 29 (25%) in group 2 had normal urine, blood pressure, and glomerular filtration rate (P less than 0.01); the disease followed a significantly more benign course in children with younger onset than in those with older onset. These observations suggest some age-related differences in the natural history of childhood IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3550023     DOI: 10.1016/s0022-3476(87)80547-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  17 in total

Review 1.  The investigation of haematuria.

Authors:  R H White
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

2.  Biopsy timing and Oxford classification variables in childhood/adolescent IgA nephropathy.

Authors:  Yuko Shima; Koichi Nakanishi; Taketsugu Hama; Masashi Sato; Hironobu Mukaiyama; Hiroko Togawa; Ryojiro Tanaka; Hiroshi Kaito; Kandai Nozu; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2014-06-07       Impact factor: 3.714

3.  Primary IgA nephropathy in children: association of clinical and pathological findings with prognosis.

Authors:  F Genel; S Arslanoğlu; B Durmaz; M Bak
Journal:  Indian J Pediatr       Date:  2001-05       Impact factor: 1.967

Review 4.  IgA nephropathy in children and adults.

Authors:  N Yoshikawa; H Nakamura; H Ito
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Asymptomatic haematuria and proteinuria: renal pathology and clinical outcome in 54 children.

Authors:  S Hisano; K Ueda
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

6.  Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).

Authors:  Yuko Shima; Koichi Nakanishi; Mayumi Sako; Mari Saito-Oba; Yuko Hamasaki; Hiroshi Hataya; Masataka Honda; Koichi Kamei; Kenji Ishikura; Shuichi Ito; Hiroshi Kaito; Ryojiro Tanaka; Kandai Nozu; Hidefumi Nakamura; Yasuo Ohashi; Kazumoto Iijima; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2018-10-03       Impact factor: 3.714

7.  Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study.

Authors:  Koichi Nakanishi; Kazumoto Iijima; Kenji Ishikura; Hiroshi Hataya; Midori Awazu; Mayumi Sako; Masataka Honda; Norishige Yoshikawa
Journal:  Pediatr Nephrol       Date:  2008-09-30       Impact factor: 3.714

8.  Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria.

Authors:  Ozlem Harmankaya; Yahya Oztürk; Taner Baştürk; Aydoğan Obek; Işin Kiliçarslan
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

9.  Course and long-term outcome of idiopathic IgA nephropathy in children.

Authors:  T Linné; U Berg; S O Bohman; L Sigström
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

Review 10.  Idiopathic immunoglobulin A nephropathy in children and adolescents.

Authors:  Ronald J Hogg
Journal:  Pediatr Nephrol       Date:  2009-02-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.